Clinical trials
Hematologic Malignancy clinical trials
Below are recruiting hematologic malignancy clinical trials, each written for real people, not researchers. We’re tracking 278 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after stem cell transplant for high-risk blood cancer
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
Bethesda, MarylandAges 12–120 - NCT04959175RecruitingPhase 1/Phase 2
Lower-dose transplant drug for older or frail patients with blood cancer
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
Bethesda, MarylandAges 12–85 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT05379738Recruiting
Exercise program to aid recovery after donor stem cell transplant
This trial tests whether an adapted physical activity (tailored exercise) can help people recover after a donor stem cell transplant for blood cancers. If you’re able to participate, the program may support strength, well-being, and recovery during the transplant process.
NiceAges 18 years+ - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT06870760Recruiting
Early blood cancer detection in Charlotte firefighters
This study looks at firefighters to find early signs of blood cancers before they become serious. It aims to learn how to catch these cancers earlier, so they can be treated sooner.
Charlotte, North CarolinaAges 40–49 - NCT05827835RecruitingPhase 1/Phase 2
CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Hangzhou, ZhejiangAges 18 years+ - NCT06208878Enrolling by invitation
Long-term follow-up for CRISPR CAR T therapy recipients
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
Duarte, CaliforniaAges 18 years+ - NCT03735992Recruiting
Mind-body sessions for people with blood cancers in remission
This trial studies whether structured mind-body group sessions can support well-being and recovery for people whose blood cancer is in remission. It may be helpful if you can safely participate in group activities and are not currently receiving active cancer treatments.
StuttgartAges 18 years+ - NCT05768269Recruiting
Follow-up study for people previously treated with cellular therapy
This trial follows up with people who already received a Century Therapeutics cellular therapy treatment. It mainly checks how you’re doing over time and whether the treatment has lasting effects.
Gilbert, ArizonaAges 18 years+ - NCT07112287Recruiting
Germline testing for myeloid cancer risk
This trial studies whether certain inherited genes increase the risk of myeloid cancers or bone marrow failure. You will provide a DNA sample via a skin biopsy to look for these genetic changes.
Boston, MassachusettsAges 18 years+ - NCT04283006RecruitingEarly Phase 1
CAR T-cell treatment for hard-to-treat B-cell blood cancers
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hangzhou, ZhejiangAges 3–70 - NCT07349849RecruitingEarly Phase 1
mRNA Drug Targeting CD19 for Blood Cancers
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07085065Recruiting
Virtual reality for pain and anxiety during blood cancer procedures
This trial tests whether watching a virtual reality experience during a medical procedure can help reduce pain and anxiety for people with blood cancers. You may be able to take part if you are getting a bone marrow biopsy, spinal tap, blood draw, or chemotherapy.
Tunis, Sfax GovernorateAges 6 years+ - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT06401356RecruitingPhase 3
Long-term study for people already taking pelabresib
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
Los Angeles, CaliforniaAges 18 years+ - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Boston, MassachusettsAges 18 years+ - NCT05708716Recruiting
Diet and brain training for people after blood cancer
This study tests whether a combined diet plan and structured brain (cognitive) training can improve thinking and memory in people who have had blood cancer. It may help survivors who already have mild-to-moderate thinking problems.
Birmingham, AlabamaAges 21 years+ - NCT05475600Recruiting
Biofeedback and relaxation for ICU patients with blood cancers
This trial tests whether guided biofeedback and relaxation techniques can help people with blood cancers while they are in the ICU. It may improve comfort and stress during critical illness, compared with standard care.
MetzAges 18–75 - NCT07135778Recruiting
Combination antifungal therapy for fungal infections in blood cancer
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06125483Recruiting
Cord blood transplant for cancer relapse after stem cell transplant
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
Suzhou, JiangsuAges 10–65 - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06532773Recruiting
Mindfulness for better sleep during blood cancer treatment
This study tests whether learning mindfulness (a way of focusing attention and calming the mind) can help improve sleep and manage symptoms for people with blood cancers who are in the hospital. It may give you coping skills to feel better during and after your treatment.
Durham, North CarolinaAges 18 years+
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic malignancy?
- Yes. Clin2 currently lists 278 recruiting hematologic malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.